Imidazolines

Health Canada announces new measures for use of neonicotinoid pesticide imidacloprid

Retrieved on: 
Wednesday, May 19, 2021

b"OTTAWA, ON, May 19, 2021 /CNW/ -Today, Health Canada released the final re-evaluation decision on the risk to human health and the environment from the neonicotinoid pesticide imidacloprid.

Key Points: 
  • b"OTTAWA, ON, May 19, 2021 /CNW/ -Today, Health Canada released the final re-evaluation decision on the risk to human health and the environment from the neonicotinoid pesticide imidacloprid.
  • This decision marks the conclusion of years of data collection, scientific assessments, and consultations.\nHealth Canada's assessment indicated that, with additional risk mitigation measures, many uses of imidacloprid products meet current standards for protection of human health and the environment.
  • Certain uses are cancelled to minimize potential risks to the environment.\nTo be approved for sale and use in Canada, all pesticides must undergo a rigorous science-based review.
  • Health Canada's Pest Management Regulatory Agency is responsible for pesticide regulation in Canada.\n"

NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)

Retrieved on: 
Wednesday, May 5, 2021

EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "Earlier this year, we were granted a similar patent in Canada, and our U.S. patent application is pending review.
  • Additionally, this newly issued patent augments the Orphan Drug Designations that we have for Quilience in both Europe and the U.S.
  • The Company\'s lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

Retrieved on: 
Monday, March 29, 2021

3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • 3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "We are very pleased to have obtained the first patent covering our novel formulation of controlled-release mazindol as we advance the development of Quilience to treat narcolepsy and other potential sleep-wake disorders," said Alex Zwyer, Chief Executive Officer of NLS.
  • "Our application for a similar patent in Europe received notice of allowance in January, and our U.S. patent application is pending review.
  • The Company's lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

Signs of Healthy Aging Found in Ergothioneine Telomere Study

Retrieved on: 
Thursday, December 10, 2020

RANCHO SANTA MARGARITA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- An in vitro study published in the Journal of Dietary Supplements , demonstrated Blue Californias ErgoActive ergothioneine helped to preserve telomere length and reduced the rate of telomere shortening under oxidative stress.

Key Points: 
  • RANCHO SANTA MARGARITA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- An in vitro study published in the Journal of Dietary Supplements , demonstrated Blue Californias ErgoActive ergothioneine helped to preserve telomere length and reduced the rate of telomere shortening under oxidative stress.
  • The in vitro study is the first time ergothioneine has been studied for its effect on telomere length.
  • Blue California provided its ErgoActive ergothioneine, which is produced by a proprietary fermentation process.
  • Our results suggest that ergothioneine as part of a healthy diet could potentially mitigate the negative effects of oxidative stress and support healthy aging by helping to preserve telomere length and reduce the rate of shortening, said Chief Science Officer, Dr. Priscilla Samuel.

Blue California Files Patent on the Use of Ergothioneine as a Support for Oxidative Stress Related Health Conditions, including COVID-19

Retrieved on: 
Tuesday, July 14, 2020

This follows Blue Californias Feb. 2020 patent application reporting the discovery that Ergothioneine inhibits the shortening of telomeres typically associated with oxidative stress.

Key Points: 
  • This follows Blue Californias Feb. 2020 patent application reporting the discovery that Ergothioneine inhibits the shortening of telomeres typically associated with oxidative stress.
  • Specifically, it claims that Ergothioneine can mitigate oxidative stress triggering the inflammatory response in many chronic conditions associated with heart disease, diabetes and cancer.
  • Also, in support of other oxidative conditions associated with oxidative stress including COVID-19 as well as other viral diseases.
  • We will be studying how Ergothioneine supplementation can support various health benefits, including immune health.

Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD

Retrieved on: 
Monday, December 9, 2019

The purpose of the trial is to evaluate the safety and efficacy of brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular redness and ocular discomfort in patients with oGVHD.

Key Points: 
  • The purpose of the trial is to evaluate the safety and efficacy of brimonidine tartrate nanoemulsion eye drop solution in the treatment of ocular redness and ocular discomfort in patients with oGVHD.
  • The trial has co-primary endpoints of ocular discomfort based on a 10-point visual analog scale and ocular redness based on a 100-point validated bulbar redness score.
  • Daniel Jorgensen, M.D., M.P.H., M.B.A., Chief Medical Officer of Ocugen, stated, The achievement of 50% enrollment is a key milestone towards the completion of this important Phase 3 trial.
  • oGVHD is a severe ocular autoimmune disease that occurs in up to 60% of allogeneic bone marrow transplant patients.

Super Antioxidant Ergothioneine Achieves GRAS Status from FDA

Retrieved on: 
Wednesday, August 21, 2019

This decision enables product manufacturers to incorporate the powerful antioxidant compound in a variety of marketable consumer products including cosmetic, beauty, food, beverages and nutraceutical applications.

Key Points: 
  • This decision enables product manufacturers to incorporate the powerful antioxidant compound in a variety of marketable consumer products including cosmetic, beauty, food, beverages and nutraceutical applications.
  • Blue California offers this proprietary ingredient, which is the only ergothioneine product on the market made by natural fermentation.
  • Ergo's super antioxidant and anti-inflammatory properties help to prevent and combat oxidative stress.
  • "Achieving GRAS status makes ErgoActivea marketable and valuable source commercially," said Hadi Omrani,director of technical and regulatory affairs.

Super Antioxidant Ergothioneine Achieves GRAS Status from FDA

Retrieved on: 
Wednesday, August 21, 2019

This decision enables product manufacturers to incorporate the powerful antioxidant compound in a variety of marketable consumer products including cosmetic, beauty, food, beverages and nutraceutical applications.

Key Points: 
  • This decision enables product manufacturers to incorporate the powerful antioxidant compound in a variety of marketable consumer products including cosmetic, beauty, food, beverages and nutraceutical applications.
  • Blue California offers this proprietary ingredient, which is the only ergothioneine product on the market made by natural fermentation.
  • Ergo's super antioxidant and anti-inflammatory properties help to prevent and combat oxidative stress.
  • "Achieving GRAS status makes ErgoActivea marketable and valuable source commercially," said Hadi Omrani,director of technical and regulatory affairs.

Clonidine (CAS 4205-90-7) - World Market Research Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2019

The "Clonidine (CAS 4205-90-7) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clonidine (CAS 4205-90-7) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report is a result of industry experts' diligent work on researching the world market of Clonidine.
  • The Clonidine global market report 2019 key points:
    The first chapter introduces the product by providing review of the most of its characteristics (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The forth chapter deals with Clonidine market trends review, distinguish Clonidine manufacturers and suppliers.

The Production & Market of Imidacloprid in China, 2019: Analysis & Outlook Through 2013-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2019

Imidacloprid, as one of the major insecticides in China, also plays an important role in the global market.

Key Points: 
  • Imidacloprid, as one of the major insecticides in China, also plays an important role in the global market.
  • China is not only an imidacloprid producer that can guarantee its own agricultural production, but also an important imidacloprid exporter in the world.
  • Getting a clear understanding of the future development trend, and identifying China's position of imidacloprid industry from a global perspective.
  • Exploring commercial opportunities of the imidacloprid industry in China under the context of the new global economic situation.